BGT226
- Product Name
- BGT226
- CAS No.
- 915020-55-2
- Chemical Name
- BGT226
- Synonyms
- BGT-226 free base;BGT226, 10 mM in DMSO;inhibit,Mammalian target of Rapamycin,BGT226,PI3K,BGT 226,Autophagy,BGT-226,Inhibitor,mTOR,Phosphoinositide 3-kinase;8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one;8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one;2H-Imidazo[4,5-c]quinolin-2-one, 1,3-dihydro-8-(6-methoxy-3-pyridinyl)-3-methyl-1-[4-(1-piperazinyl)-3-(trifluoromethyl)phenyl]-
- CBNumber
- CB52731024
- Molecular Formula
- C28H25F3N6O2
- Formula Weight
- 534.53
- MOL File
- 915020-55-2.mol
BGT226 Property
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- M226705
- Product name
- 8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl)-3-(trifluoromethyl)phenyl-1H-imidazol[4,5-c]quinolin-2(3H)-one
- Packaging
- 2.5mg
- Price
- $260
- Updated
- 2021/12/16
- Product number
- SYN1178A
- Product name
- BGT-226freebase
- Packaging
- 100mg
- Price
- $1615
- Updated
- 2021/12/16
BGT226 Chemical Properties,Usage,Production
Uses
8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl)-3-(trifluoromethyl)phenyl-1H-imidazol[4,5-c]quinolin-2(3H)-one is an intermediate used in the screening of anti-prostate cancer drug targeting PI3K-AKT-mTOR pathway.
Definition
ChEBI: BGT226 free base is an imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor. It has a role as an antineoplastic agent, a mTOR inhibitor and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is an imidazoquinoline, a N-arylpiperazine, a member of pyridines, an organofluorine compound and an aromatic ether. It is a conjugate base of a BGT226(1+).
in vivo
BGT226 (2.5 and 5 mg/kg; oral administration for 21 days in male athymic mice) causes 34.7% and 76.1% reduction of the tumor growth on day 21 compared with control[2].
| Animal Model: | Male athymic mice (strain BALB/cAnN.Cg-Foxn1nu/CrlNarl) with FaDu cell xenografted mouse model[2] |
| Dosage: | 2.5 and 5 mg/kg |
| Administration: | Oral administration; 21 days |
| Result: | Caused 34.7% and 76.1% reduction of the tumor growth. |
IC 50
PI3Kα: 4 nM (IC50); PI3Kβ: 63 nM (IC50); PI3Kγ: 38 nM (IC50); mTOR; Autophagy